Figure 2

Effect of dinaciclib on patient derived xenograft cells. (A) Treatment of CHNG6 cells with dinaciclib for 24 h substantially reduced cell proliferative ability of these cells and the IC₅₀ was in nanomolar range. (B) Cell cycle analysis indicated G0/G1 blockade and suppression in S-phase population with dinaciclib treatment (8 nM) for 24 h when compared to vehicle treatment. (C) Dinaciclib treatment (8 nM) of CHNG6 cells for 24 h substantially induced apoptosis when compared to vehicle treatment. (D) CHNG6 cells treated with dinaciclib (8 nM) for 24 h exhibited increased caspase 3/7 activity when compared to vehicle treatment.